Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Cash from Financing Activities: 2017-2025

Historic Cash from Financing Activities for Protagonist Therapeutics (PTGX) over the last 9 years, with Sep 2025 value amounting to $5.7 million.

  • Protagonist Therapeutics' Cash from Financing Activities fell 53.04% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 million, marking a year-over-year increase of 7.65%. This contributed to the annual value of $25.9 million for FY2024, which is 84.83% down from last year.
  • As of Q3 2025, Protagonist Therapeutics' Cash from Financing Activities stood at $5.7 million, which was up 93.47% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Cash from Financing Activities registered a high of $125.4 million during Q2 2021, and its lowest value of $527,000 during Q4 2023.
  • For the 3-year period, Protagonist Therapeutics' Cash from Financing Activities averaged around $19.7 million, with its median value being $7.2 million (2024).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 99.46% in 2022, then skyrocketed by 15,807.65% in 2023.
  • Over the past 5 years, Protagonist Therapeutics' Cash from Financing Activities (Quarterly) stood at $2.2 million in 2021, then slumped by 74.55% to $553,000 in 2022, then fell by 4.70% to $527,000 in 2023, then surged by 664.90% to $4.0 million in 2024, then tumbled by 53.04% to $5.7 million in 2025.
  • Its Cash from Financing Activities stands at $5.7 million for Q3 2025, versus $2.9 million for Q2 2025 and $11.4 million for Q1 2025.